Patients sensitized to common aeroallergen Patients not sensitized to common aeroallergen nor to SE Patients not sensitized to common aeroallergen and sensitized to SE P value
n 31 11 12
Age (years) 57.00 [51.50, 68.50] 60.00 [55.50, 68.00] 55.00 [50.25, 61.50] 0.466
Gender (% male) 20 (64.5) 2 (18.2) 4 (33.3) 0.016
BMI 23.00 [22.00, 27.00] 27.00 [23.00, 34.50] 25.00 [22.00, 28.00] 0.207
CRSwNP (%) 6 (19.4) 4 (36.4) 7 (58.3) 0.050
FEV1 (predicted %) 67.00 [54.75, 81.75] 72.50 [59.75, 82.25] 77.00 [65.50, 86.50] 0.589
Total IgE measurment (kU/l) 289.00 [112.50, 1115.00] 78.00 [16.50, 127.00] 184.50 [66.00, 500.00] 0.014
Eosinophil cells blood count ( G/L) 0.25 [0.13, 0.65] 0.22 [0.06, 0.58] 0.16 [0.05, 0.74] 0.811
Oral cortisteroid at baseline (%) 6 (19.4) 6 (60.0) 7 (63.6) 0.008
Oral corticosteroid dose at baseline 0.00 [0.00, 0.00] 8.75 [0.00, 13.75] 10.00 [0.00, 20.00] 0.010
Rate of severe exacerbation the year before evaluation 1.00 [0.50, 4.00] 4.00 [1.50, 8.00] 4.00 [2.50, 6.00] 0.061
Omalizumab efficacy (%) 20 (64.5) 6 (54.5) 6 (50.0) 0.694